Hubei Biocause Pharmaceutical (000627.SZ) announces a forecasted net loss of between 500 million and 750 million yuan for the fiscal year 2024.

20/01/2025

GMT Eight

Hubei Biocause Pharmaceutical (000627.SZ) issued an announcement, the company expects a net loss of 500 million to 750 million yuan attributable to shareholders of the listed company in 2024.

Jointo Energy Investment (000600.SZ) has forecasted a net profit of approximately 520 million yuan for the year 2024, representing a year-on-year growth of 175.68%.

Guangdong New Grand Long Packing (002836.SZ) expects a net profit of 59-73 million yuan for the year 2024, an increase of 203.03% - 274.94% year-on-year.

Contact: contact@gmteight.com

Hubei Biocause Pharmaceutical (000627.SZ) announces a forecasted net loss of between 500 million and 750 million yuan for the fiscal year 2024.

RECOMMEND

HK ASIA HLDGS(01723) plans to change its name to "Evermoon Holdings Limited"

HK ASIA HLDGS (01723) got a discount of about 5.26% to complete the full purchase offer and resume trading on January 21.

METASURFACE (08637) Controlling shareholder Caina Technology reward plan, and a total of 9.75 million shares of bonus shares granted under the share incentive plan.